Home › NDC Lookup › RxCUI directory › RxCUI 1000085

Alcaftadine 2.5 MG/ML Ophthalmic Solution — RxCUI 1000085

RxNorm drug concept · Semantic clinical drug
RxCUI 1000085 Semantic clinical drug · SCD ● Current RxNorm concept 5 FDA products 11 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI1000085
Official nameAlcaftadine 2.5 MG/ML Ophthalmic Solution
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asalcaftadine 0.25 % Ophthalmic Solution
FDA products mapped5
Package NDCs mapped11
Reported Medicaid activity (SDUD)1,540 prescriptions · 7 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Alcaftadine Ophthalmic: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Lastacaft helps prevent the itching that comes with eye allergies (allergic conjunctivitis) — it's not a cure, but it can significantly reduce how much your eyes itch when allergen...
  • What exactly does Lastacaft do — will it stop my eye allergies completely?
  • No — you need to wait at least 10 minutes before reinserting your contacts. The preservative in Lastacaft can be soaked up by soft contact lenses, which isn't good for your eyes or...
  • Can I put my contact lenses back in right after using these drops?
📖 Read our full Alcaftadine Ophthalmic guide →

🕸️ Concept Web — How Alcaftadine 2.5 MG/ML Ophthalmic Solution Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Alcaftadine 2.5 MG/ML Ophthalmic Solution RxCUI 1000085

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Alcaftadine 1000082
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Lastacaft 1000086
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Alcaftadine Ophthalmic Solution 1000084
    • Alcaftadine Ophthalmic Product 1154608
    • Alcaftadine Ophthalmic Solution [Lastacaft] 1000088
    • Lastacaft Ophthalmic Product 1175652
    • Ophthalmic Solution 7670
    • Ophthalmic Product 1151135
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Alcaftadine 2.5 MG/ML SCDC · 1000083
  • Alcaftadine Ophthalmic Solution SCDF · 1000084
  • Alcaftadine Ophthalmic Product SCDG · 1154608

Brand-Name Concepts

📦 FDA Products & Package NDCs

5 products · 11 package NDCs
11 package NDCs map to RxCUI 1000085 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00023-4290-01 1 BOTTLE, PLASTIC in 1 CARTON (0023-4290-01) / 1 mL in 1 BO... LASTACAFT Allergan, Inc. 2010-11-01
00023-4291-01 1 BOTTLE, PLASTIC in 1 CARTON (0023-4291-01) / 1 mL in 1 BO... LASTACAFT Allergan, Inc. 2021-12-01
00023-4291-05 1 BOTTLE, PLASTIC in 1 CARTON (0023-4291-05) / 5 mL in 1 BO... LASTACAFT Allergan, Inc. 2021-12-01
00023-4291-06 1 BOTTLE, PLASTIC in 1 CARTON (0023-4291-06) / 5 mL in 1 BO... LASTACAFT Allergan, Inc. 2021-12-01
00023-4291-07 2 BOTTLE, PLASTIC in 1 CARTON (0023-4291-07) / 5 mL in 1 BO... LASTACAFT Allergan, Inc. 2021-12-01
00023-4291-10 2 BOTTLE, PLASTIC in 1 CARTON (0023-4291-10) / 5 mL in 1 BO... LASTACAFT Allergan, Inc. 2021-12-01
58602-0605-40 1 BOTTLE in 1 CARTON (58602-605-40) / 5 mL in 1 BOTTLE Alcaftadine Aurohealth LLC 2023-06-23
58602-0605-42 2 BOTTLE in 1 CARTON (58602-605-42) / 5 mL in 1 BOTTLE Alcaftadine Aurohealth LLC 2023-06-23
62332-0147-03 1 BOTTLE in 1 CARTON (62332-147-03) / 3 mL in 1 BOTTLE alcaftadine Alembic Pharmaceuticals Inc. 2024-10-02
68083-0649-01 1 BOTTLE in 1 CARTON (68083-649-01) / 3 mL in 1 BOTTLE Alcaftadine Gland Pharma Limited 2024-03-01
68083-0649-02 2 BOTTLE in 1 CARTON (68083-649-02) / 3 mL in 1 BOTTLE Alcaftadine Gland Pharma Limited 2024-03-01
Observed labelers: Allergan, Inc. (6) · Aurohealth LLC (2) · Gland Pharma Limited (2) · Alembic Pharmaceuticals Inc. (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ml · median
$2.8333
Range $2.8333–$2.8333 · middle 50% $2.8333–$2.8333 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.